Anti-SMN1 Monoclonal Antibody for WB, IHC-P, ELISA - Q16637

Core Product Specifications and Parameters

Biological Background: SMN1 Function and Localization

• Protein identity and isoforms: SMN1 encodes the survival motor neuron protein, also known as component of gems 1 (Gemin-1). It is a key structural component of the SMN complex, with a molecular weight of ~32 kDa.
• Core function in snRNP assembly: SMN1 forms the backbone of the SMN complex, which catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. It accepts Sm proteins from the CLNS1A chaperone and, together with GEMIN2, gathers Sm complex subunits. Related references: PMID:18984161 PMID:17178713
• Spliceosome assembly details: Binding of snRNA to the assembling Sm core triggers eviction of the SMN complex, allowing SNRPD3 and SNRPB to complete core snRNP formation. This process is essential for pre-mRNA splicing. Related references: PMID:21816274 PMID:22101937 PMID:31799625
• Role in U12 intron splicing: SMN1 ensures correct splicing of U12 intron-containing genes, which is critical for the development of motor and proprioceptive neurons. Related references: PMID:23063131
• Additional nuclear functions: SMN1 is required for resolving RNA-DNA hybrids (R-loops) created by RNA polymerase II in transcription terminal regions, contributing to proper transcription termination. Related references: PMID:26700805
• Subcellular localization: SMN1 localizes to the nucleus (gems and Cajal bodies), cytoplasm, cytoplasmic granules, and is also found in neuron projections, axons, and at the Z line of sarcomeres.
• Tissue specificity: Expressed widely, with high levels in brain, kidney, liver, and spinal cord; moderate levels in skeletal and cardiac muscle; and low levels in fibroblasts and lymphocytes. Also present in osteoclasts and mononuclear cells (at protein level).
• Post-translational modifications and keywords: SMN1 undergoes acetylation, phosphorylation, isopeptide bond formation, and ubiquitin-like conjugation. It is associated with mRNA processing, neurodegeneration, neurogenesis, and alternative splicing, and is linked to disease variants in spinal muscular atrophy (SMA).

Experimental Guidance and Technical Tips

• The immunogen corresponds to a central region (amino acids 103–200) of human SMN1. This region is well conserved, and the antibody is expected to recognize the native protein; however, epitope-specific validation is recommended for your intended application.
• For Western blot, a band near 32 kDa is anticipated in human and rat samples. Expression levels may vary; highest in brain, kidney, liver, and spinal cord. Use these tissues as positive controls and consider loading appropriate amounts based on expected expression.
• In IHC-P, nuclear gems and Cajal body staining may be observed, along with cytoplasmic localization in some cell types. Optimize antigen retrieval and antibody dilution for your specific tissue and fixation conditions.
• For ELISA, the antibody may serve as a capture or detection reagent. Empirical testing with your assay format and antigen is essential to confirm compatibility.
• Cross-reactivity with rat is reported; if working with other species, in-house validation is advised.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, research laboratories, and institutes seamless access to a comprehensive portfolio of IVD raw materials, technical services, and development consulting. For SMN1-related projects, we supply validated monoclonal antibodies, bulk ancillary reagents, and rare target sourcing, streamlining your research into splicing mechanisms, neurodegeneration, and spinal muscular atrophy. Partner with CamelBio to accelerate your IVD development from concept to clinic.